Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.8%. By the end of trading, Pfizer fell $0.73 (-2.5%) to $28.28 on average volume. Throughout the day, 48,566,986 shares of Pfizer exchanged hands as compared to its average daily volume of 33,863,000 shares. The stock ranged in price between $28.10-$28.90 after having opened the day at $28.86 as compared to the previous trading day's close of $29.01. Other companies within the Drugs industry that declined today were:
), down 66.8%,
), down 13.2%,
), down 11.4% and
), down 11.4%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $206.0 billion and is part of the health care sector. The company has a P/E ratio of 20.5, above the S&P 500 P/E ratio of 17.7. Shares are up 15.7% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Pfizer a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Pfizer Ratings Report.
On the positive front,
), down 39.5%,
), down 14.1%,
), down 10.1% and
), down 10.1% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.